An Exclusive Interview with Edith Perez, MD

Share this content:
Edith A. Perez
Edith A. Perez
An Exclusive Interview with Edith Perez, MD
Deputy Director, Mayo Clinic Cancer Center
Group Vice-Chair, Alliance for Clinical Trials in Oncology
Serene M. and Frances C. Durling
Professor of Medicine, College of Medicine
Director of the Breast Program
Mayo Clinic
Jacksonville, Florida

Dr. Edith Perez, an internationally renowned expert in the treatment of breast cancer, offers her comments on the 2012 Annual Meeting of the American Society of Clinical Oncology and the standard of care for breast malignancies.

Dr. Perez discusses her ASCO 2012 abstract entitled: “Effect of PTEN protein expression on benefit to adjuvant trastuzumab in early-stage HER2+ breast cancer in NCCTG adjuvant trial N9831": Play
Dr. Perez discusses the translation of the PTEN adjuvant data into the development of future clinical trials: Play
Dr. Perez discusses her presentation of the VELVET trial: a phase 2 trial in progress to assess combination therapy, including pertuzumab, trastuzumab, and vinorelbine, in HER2-positive metastatic breast cancer: Play

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs